rEECur
Research type
Research Study
Full title
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
IRAS ID
149572
Contact name
Jaclyn Brown
Contact email
Sponsor organisation
University of Birmingham
Eudract number
2014-000259-99
ISRCTN Number
ISRCTN36453794
Research summary
rEECur is a randomised study to compare four chemotherapy regimens to see which is the best at treating recurrent or refractory Ewing sarcoma. Ewing sarcoma is a type of bone cancer. Recurrent Ewing sarcoma means Ewing sarcoma that has come back after being treated. Refractory Ewing sarcoma means Ewing sarcoma that has grown or progressed while being treated. Ewing sarcoma is rare and running a study such as this requires funding and collaboration across many different treatment centres and countries. The logistics behind running such a study are not trivial and as a result rEECur is the first study to directly compare different chemotherapy regimens in this disease setting.
Most doctors treat recurrent and refractory Ewing sarcoma with chemotherapy. However, although several chemotherapy regimens are available to treat this disease, we do not know which is the best regimen to use. We are primarily interested in finding out which regimen is most effective at making tumour deposits shrink and, in the longer term, at curing the disease or providing prolonged disease control. We will also determine which regimen has the most side effects, which is associated with the most time spent in hospital and which has the greatest effect on quality of life.
The results will help us to know which chemotherapy regimen is the best to use for patients with this disease. It will also allow us to inform patients about the relative burden of side effects associated with each regimen, allowing individual patients and/or parents to make an informed choice about how to be treated.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
14/NW/1110
Date of REC Opinion
29 Aug 2014
REC opinion
Further Information Favourable Opinion